Page 1

+ immunovia INTERIM REPORT JANUARY - MARCH 2021 Key Indicators SEK thousand unless otherwise stated 2021 Jan - March 2020 2020 2019 Jan - March Full year Full year Net sales 123 14 362 356 Operating earnings -29,082 -32,114 -134,343 -114,248 Earnings before tax -23,445 -27,751 -146,033 -114,517 Net earnings -23,445 -27,751 -146,033 -114,521 Earnings per share before dilution ( SEK ) -1.04 -1.41 -6.84 -5.85 Earnings per share after dilution ( SEK ) -1.04 -1.41 -6.84 -5.85 Equity ratio ( % ) 90 83 91 85 Number of shares at the end of the period 22,631,581 19,654,853 22,631,581 19,654,853 Significant events January - March 2021 Immunovia announced that the company was on track to start of sales and that all necessary samples for the blinded validation study had been secured . Immunovia announced that more than 3,000 blood samples had been collected for the company's large prospective study PanFAM - 1 . The study is designed to support the path to cost reimbursement for Immunovia's blood - based test IMMray ™ PanCan - d . All blood samples will be analyzed during the second half of 2021 Immunovia published new data for the development phases of IMMray ™ PanCan - d . The data was presented in two posters for the optimization study and the commer- cial test model study which demonstrated how the test performed in different clinical indications . Immunovia improved the test performance of IMM- ray ™ PanCan - d in high - risk patients with symptoms . A retrospective clinical study showed that Immunovia's test now detects pancreatic cancer ( at all stages ) with 92 % specificity and 81 % sensitivity for this cohort , which is in line with the results presented in the previous commerci- al test model study . Immunovia successfully completed the blinded clinical validation study for IMMray ™ PanCan - d in the US . Stage I / II pancreatic cancer was detected with 98 % specificity and 85 % sensitivity in cohorts of patients with familial / hereditary risk . The validation study is the final milestone before applying for a Massachusetts State License and CLIA registration for the Immunovia Dx Laboratory in the US . Significant events after the period Immunovia's blood test IMMray ™ PanCan - d was highlighted at a seminar organized by the largest patient organization in the US , the Pancreatic Cancer Action Network . Dr. Rosalie C. Sears , Co - Director of the Bren- den - Colson Center for Pancreatic Care and Professor at Oregon Health & Science University , as well as advisor to PANCAN , expressed her enthusiasm for Immunovia's blood test and the test's ability to detect early stage I and Il pancreatic cancer . As a result of updated guidelines , a new assessment was made of the size of the market in the US for IMMray ™ PanCan - d in the familial / hereditary risk group . Immunovia's new estimate shows that 315,000 - 350,000 individuals have a familial / hereditary risk of pancreatic cancer and would qualify to be included in surveillance programs . IMMUNOVIA AB EARLY DETECTION